Loading, Please Wait...

CST: 17/07/2019 00:07:09   

Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market

145 Days ago

NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office located at 1777 Sentry Parkway West in Blue Bell, Pa. The approximately 12,000 square-feet office space will serve as Achillion’s executive offices and clinical operations base while the Company maintains its current significant research presence in New Haven, Connecticut.

“Achillion continues to expand our clinical development, clinical operations and regulatory teams as we accelerate our oral, small molecule complement inhibitor programs into late-stage development and commercialization,” said Joe Truitt, President and Chief Executive Officer at Achillion. “We believe this additional space and proximity to talented and innovative individuals in the Philadelphia area will bolster our growing commercial capabilities as we develop treatments for patients with complement-mediated diseases.”

The new space opened for operations on January 1, 2019.

About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Factor D is an essential enzyme in the alternative pathway of the complement system, a part of the innate immune system. Achillion is initially focusing its drug development activities on alternative pathway-mediated diseases where there are no approved therapies or where existing therapies are inadequate for patients. Potential indications being evaluated for its compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN). Each of the product candidates in the Company’s oral factor D portfolio was discovered in its laboratories and is wholly owned. To advance its investigational product candidates into Phase 3 clinical trials and commercialization, the Company plans to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. More information is available at http://www.achillion.com.

Corporate Communications:
Susanne Heinzinger
Senior VP, Corporate Communications
Achillion Pharmaceuticals, Inc.
Tel. 215-709-3055
sheinzinger@achillion.com

Media:
Jon Pappas
Media Relations
W2O Group
Tel. (646) 847-0303
jpappas@w2ogroup.com

Source: Achillion Pharmaceuticals, Inc. 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?